Copyright
©The Author(s) 2025.
World J Diabetes. Jan 15, 2025; 16(1): 92711
Published online Jan 15, 2025. doi: 10.4239/wjd.v16.i1.92711
Published online Jan 15, 2025. doi: 10.4239/wjd.v16.i1.92711
Figure 4 High glucose intervention resulted in a considerable rise in sodium-glucose cotransport protein 1 protein levels.
A and B: Western blot of sodium-glucose cotransport protein 1 (SGLT1) expression in mesangial cells and proximal tubular cells; C and D: Western blot of SGLT1 expression in normal glucose and high glucose treatment with mesangial cells; E: Glucose consumption in 5.5 mmol/L glucose; F: Glucose consumption in 25 mmol/L glucose. The values are presented as the mean ± standard error of the mean. aP < 0.05; bP < 0.01. MIZ: Mizagliflozin; SGLT1: Sodium-glucose cotransport protein 1.
- Citation: Lin ZM, Gao HY, Shi SH, Li YT. Mizagliflozin ameliorates diabetes induced kidney injury by inhibitor inhibit inflammation and oxidative stress. World J Diabetes 2025; 16(1): 92711
- URL: https://www.wjgnet.com/1948-9358/full/v16/i1/92711.htm
- DOI: https://dx.doi.org/10.4239/wjd.v16.i1.92711